HealthQuill
Pfizer Inc. will buy Matsera Inc. for $7.3 billion to eye at least four experimental drugs in the rapidly growing obesity market after it scrapped development of its own weight-loss pill in April this year.
Drugs Health Pharma

Pfizer to buy Matsera Inc. for $7.3 billion, eyes 4 anti-obesity drugs

Pfizer Inc. will buy Matsera Inc. for $7.3 billion to eye at least four experimental drugs in the rapidly growing obesity market after.

Read More
A specially formulated eye drop to treat presbyopia or near vision loss may get rid of the reading glasses, according to a study presented at the European Society of Cataract and Refractive Surgeons (ESCRS).
Health Medical Research

New eye drop for farsighted may help get rid of reading glasses: Research

A specially formulated eye drop to treat presbyopia or near vision loss may get rid of the reading glasses, according to a study.

Read More
At least 12 people have died, and 740 new patients were admitted to hospitals as dengue cases in the South Asian nation of Bangladesh registered the largest single-day rise last week.
Climate Drugs Health

Bangladesh reports highest single-day rise in dengue cases last week

At least 12 people have died, and 740 new patients were admitted to hospitals as dengue cases in the South Asian nation of.

Read More
In India, teacher training courses cover pedagogy, subject knowledge, classroom management, and child psychology. But are we truly preparing psychologically healthy adults for one of the most emotionally demanding jobs in the world? Mounting evidence suggests the answer is no.
Health Opinion Research

Psychological test for teachers matter, one must look beyond their resume

In India, teacher training courses cover pedagogy, subject knowledge, classroom management, and child psychology. But are we truly preparing psychologically healthy adults for.

Read More
The US drug regulator, the Food and Drug Administration, has approved Merck & Co.’s new formulation of its cancer drug Keytruda that can be administered under the skin for adults.
Drugs Health Pharma

US approves Merck’s skin injectable version of cancer drug Keytruda

The US drug regulator, the Food and Drug Administration, has approved Merck & Co.’s new formulation of its cancer drug Keytruda that can.

Read More
A child’s brain gets excessively or abnormally active when they are not treated for anxiety disorders, according to a study by the US National Institutes of Health.
Health Research

Study uncovers early brain damage in athletes in contact sports

HQ Team September 18, 2025: A new study funded by the National Institutes of Health (NIH) reveals that repeated head impacts from contact.

Read More
Swiss healthcare multinational F. Hoffmann-La Roche AG will acquire US-based 89bio Inc. for a deal worth up to $3.5 billion to expand its metabolic disease portfolio.
Drugs Health Pharma

Roche to buy 89bio Inc for $3.5 billion to expand metabolic disease portfolio

Swiss healthcare multinational F. Hoffmann-La Roche AG will acquire US-based 89bio Inc. for a deal worth up to $3.5 billion to expand its.

Read More
Merck & Co. got approval from the US Food and Drug Administration for a pill to treat a rare type of tumour in adults and children aged above 12 years, according to a statement.
Health Research

India’s cancer burden: Rising cases and gender disparities

HQ Team September 17, 2025: A recent comprehensive study based on data from India’s National Cancer Registry Programme has highlighted significant regional variations.

Read More
AstraZeneca’s lung cancer drug, Tagrisso, reduced the risk of death by 51% in the early stages of the disease, according to a company statement.
Drugs Health

AstraZeneca’s asthma drug fails end-stage trial in COPD

HQ Team September 17, 2025: AstraZeneca’s asthma drug Fasenra (benralizumab) has  failed to meet its primary goal in a Phase III trial for.

Read More
https://www.novartis.com/research-and-development/research-disease-areas/cardiovascular-and-metabolic-disease-research-novartis
Drugs Health Pharma

Novartis signs $5.2 billion pact with China’s Argo Biopharmaceutical

HQ Team September 4, 2025: China’s Argo Biopharmaceutical Co., Ltd., and Switzerland’s Novartis AG have inked a $5.2 billion pact to develop new.

Read More